Identification of six novel variants in Waardenburg syndrome type II by next-generation sequencing

Shumin Ren | Xiaojie Chen | Xiangdong Kong | Yibing Chen | Qinghua Wu | Zhihui Jiao | Huirong Shi

Abstract

Background: Waardenburg syndrome (WS) is a dominantly inherited, genetically heterogeneous auditory-pigmentary syndrome characterized by nonprogressive sensorineural hearing loss and iris discoloration. This study aimed to investigate the underlying molecular pathology in Chinese WS families.

Methods: A total of 13 patients with Waardenburg syndrome type II (WS2) from six unrelated Chinese families were enrolled. We investigated the mutation profile of genes related to congenital deafness in these families through a targeted sequencing technology and validated the candidate variants by Sanger sequencing.

Results: We identified six novel variants in microphthalmia-associated transcription factor (MITF) and SRY-box 10 (SOX10), which were predicted to be disease causing by in silico analysis. Our results showed that mutations in SOX10 and MITF are two major causes of deafness associated with WS, and de novo mutations were frequently found in probands with SOX10 mutations but not in those with MITF mutations.

Conclusion: Results showed that targeted next-generation sequencing (NGS) enabled us to detect disease-causing mutations with high accuracy, stability, speed and throughput. Our study extends the pathogenic mutation spectrum of MITF and SOX10.

Keywords

MITF, next-generation sequencing, SOX10, Waardenburg syndrome

1 | INTRODUCTION

Waardenburg syndrome (WS) is a clinically and genetically heterogeneous hereditary auditory pigmentary disorder characterized by congenital sensorineural hearing loss and iris discoloration. Many genes have been linked to WS, including paired box 3 (PAX3) (OMIM 606597), MITF (OMIM 156845), snail family zinc finger 2 (SNAI2) (OMIM 602150), endothelin receptor type B (EDNRB) (OMIM 131244), endothelin 3 (EDN3) (OMIM 131242), and SOX10 (OMIM 602229). These genes are involved in the formation and development of several types of cells, including pigment-producing cells called melanocytes. Mutations in any of these genes disrupt the normal development of melanocytes, leading to abnormal pigmentation of the skin (Pingault et al., 2010). Offspring of individuals with WS have a 50% chance of inheriting the pathogenic mutation, and therefore, an exact description of the mutations responsible for the WS is crucial for the genetic counseling of WS patients and their families.
As conventional gene-by-gene sequencing is too costly and time-consuming, recently, next-generation sequencing (NGS) has been introduced to analyze the exons and flanking intronic regions of genes with clinical relevance. NGS is appropriate for a variety of gene sequencing indications, providing lower turnaround times, lower cost, and a more comprehensive coverage of target regions (Ku et al., 2012; Lee et al., 2014; Lohmann & Klein, 2014; Ng et al., 2010, 2009). We performed NGS to screen all possible genes associated with WS and congenital deafness simultaneously and identified six novel variants in MITF and SOX10 in patients. Further analysis by Sanger sequencing of patients and their parents revealed three de novo occurrence of variants. Our findings show that NGS can be a useful tool for the identification of pathogenic gene variants in WS patients.

2 | MATERIALS AND METHODS

2.1 | Ethical compliance

Clinical investigations were conducted according to the Declaration of Helsinki, and the study was approved by the institutional review board of the Medical Ethics Committee of the First Affiliated Hospital of Zhengzhou University.

2.2 | Patients and samples

All patients with WS of Chinese Han nationality were identified at the First Affiliated Hospital of Zhengzhou university (January 2016 to August 2019). Detailed examinations were performed on all patients by medical specialists. The following tests were conducted: observation of skin pigmentation, hair color, joints, skeleton muscular system, digestion, nerves, ophthalmology and otology, and an assessment of intelligence. In addition, a detailed audiological examination was conducted on the probands. The clinical audiology assessment included pure tone test, acoustic immittance, auditory steady-state response, auditory brainstem response (ABR), otocoustic emission, test of study ability and psychiatric behavior development, ossa temporale computerized tomography, and magnetic resonance imaging. There were 13 patients with WS (from six families) aged 2 months to 71 years, and nine unaffected family members (WS01-II:1, WS02-II:3, WS03-II:3, WS04-I:1, WS04-I:2, WS05-I:1, WS05-I:2, WS06-I:1, and WS06-I:2) who agreed to take part in the study following audiological and general physical examinations. Among the six families, families WS04 to WS06 were sporadic cases in which the pedigrees did not reveal any history of WS features in the three last generations, while the remaining families had multiple affected individuals (Figure 1). Characteristics of patients are presented in Table 1. Two hundred randomly selected normal individuals were also included in this study. Documented permission of identifiable patient images from patients or legal guardians were obtained by written patient consent. Written informed consent was obtained from all adult subjects and guardians on behalf of the children, prior to clinical evaluation and blood sample collection.

2.3 | DNA extraction

Whole genomic DNA was isolated from blood samples using TIANamp Blood DNA Kit (Tiangen Biotech Co., Ltd.) and quantified by an ultraviolet spectrophotometer Du800 (Beckman Coulter, Inc.). The DNA was subsequently stored at −20°C until further use.

FIGURE 1 Pedigrees of the Waardenburg syndrome families. Pedigrees of families (a) 01, (b) 02, (c) 03, (d) 04, (e) 05, and (f)06
2.4 Mutational analysis

Genomic DNA was enriched using a customized panel (MyGenostics), which was designed to capture 159 known genes (Table S1) related to hearing loss to detect the genetic cause of the WS families, and then sequenced on the Illumina NextSeq500 system in our clinical laboratory. Raw sequence reads were processed and aligned to the hg19 human reference sequence with the Burrows-Wheeler Aligner (BWA, version 0.7.5). Single-nucleotide polymorphism (SNP) and short indel candidates were identified, and these variants were annotated by ANNOVAR to filter SNPs reported in public databases (dbSNP, gnomAD, ESP, Clinvar, 1000 Genomes and ExAC) and the HGMD Professional database. Exonic sequence alterations and intronic variants at exon-intron boundaries, with unknown frequency or minor allele frequency (MAF) <1% and not present in the homozygous state in those databases were retained. The Sorting Intolerant From Tolerant (SIFT), Polymorphism Phenotyping v2 (PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/) and MutationTaster (http://www.mutationtaster.org/) algorithms were used to predict the effects of variants on protein function. Nucleotide conservation between species was evaluated using the UCSC Genome Browser Database (https://genome.ucsc.edu/). The candidate variants identified by NGS were confirmed by conventional Sanger sequencing. The carrying situation of the mutations of their family members and 200 randomly selected normal individuals were also tested by Sanger sequencing. Polymerase chain reaction (PCR) primers (Table 2) were designed by Primer premier 5.0 software and were synthesized by Shanghai Shangon Co., Ltd. Capillary electrophoresis apparatus (ABI 3130XL, USA) and the dGTP BigDye® Terminator sequencing kit (ABI, USA) were used for Sanger sequencing.

3 RESULTS

3.1 Clinical findings

Before genetic testing, probands WS01 and WS02 were primarily diagnosed with nonsyndromic deafness, and the other four probands (WS03 to 06) were diagnosed with WS2 based on their calculated W index (<1.85) and the absence of musculoskeletal anomalies and intestinal aganglionosis. After genetic diagnosis, further examination of the probands...
pathogenicity analysis. A heterozygous deletion mutation, c.355_356insT-(WS02-II:3) with anormal phenotype did not have this mutation but their hearing was normal. Another uncle of the proband's mother (WS02-II:2) had the same heterozygous mutation. The family member (WS01-II:1) with normal phenotype did not have this mutation. The same mutation was detected in WS02-III:1 which was predicted to be deleterious by in silico analysis using MutationTaster. We regarded this variant as the best candidate and subsequently validated it by Sanger sequencing. We also tested and verified the mutation in nuclear members of the family. We found that all patients (WS01-I:2, II:2 and II:3) had the same heterozygous mutation. The family member (WS01-II:1) with normal phenotype did not have this mutation (Table 3; Figure 3).

A heterozygous splicing mutation, c.859-1G>A, of MITF was detected in WS02-III:1 which was predicted to be deleterious by MutationTaster. The same mutation was detected in the proband's mother, uncle (WS02-II:2) and grandmother. Three of them only had brown freckles on the face but their hearing was normal. Another uncle of the proband (WS02-II:3) with anormal phenotype did not have this mutation. A heterozygous deletion mutation, c.355_356insT-CAGGAGGCC, of SOX10 was detected in WS03-I:1 which was predicted to be deleterious by in silico analysis using MutationTaster, and other patients (WS03-II:1 and II:2) also had the heterozygous mutation. Another son of the proband (WS03-II:3) with normal phenotype did not have this mutation (Table 3; Figure 3).

Heterozygous mutations, c.1106_1107insTGGGGCCCATCAGACTA, c.511T>C (p.Y171H) and c.91_100del in SOX10 were detected in WS04-II:2, WS05-II:1, and WS06-II:1, respectively, by NGS and confirmed by Sanger sequencing. c.91_100del were predicted to be deleterious by MutationTaster, c.511T>C (p.Y171H) was predicted to be deleterious by SIFT, PolyPhen-2 and MutationTaster. The three proband's parents did not carry corresponding mutations as determined by Sanger sequencing indicating that the mutations occurred de novo (Table 3; Figure 3).

All of the six mutations have not been reported by previous studies or recorded in the public database (dbSNP, gnomAD, ESP, Clinvar, 1000 Genomes and ExAC) confirming the six mutations were novel. Moreover, these mutations were not found in unaffected family members or in 200 unrelated healthy control subjects.

Compared with homologous proteins of the mouse, rat, bovine, pig, dog, horse, and zebrafish, these six novel missense mutations identified in our study are conserved in other species (Figure 4).

### 3.2 Identification of mutations and pathogenicity analysis

After screening of all WS-related genes and congenital deafness, a heterozygous nonsense mutation, c.859G>T, of MITF was detected through gene panel sequencing of WS01-II:2. The variant was predicted to be deleterious by MutationTaster. We regarded this variant as the best candidate and subsequently validated it by Sanger sequencing. We also tested and verified the mutation in nuclear members of the family. We found that all patients (WS01-I:2, II:2 and II:3) had the same heterozygous mutation. The family member (WS01-II:1) with normal phenotype did not have this mutation (Table 3; Figure 3).

### 4 DISCUSSION

Waardenburg syndrome, coined by Dutch ophthalmologist Petrus Johannes Waardenburg, is a neurocristopathy composed of hearing impairment and pigmentary abnormalities of eyes, skin and hair (Waardenburg, 1951). Its prevalence is estimated to be 1/42,000, and it is responsible for 1%–3% of total congenital deafness (Read & Newton, 1997). It is often described as an autosomal dominantly inherited disorder of neural crest cells (NCCs), but we now know that WS is clinically and genetically heterogeneous, and that not all forms are dominantly inherited.

Four subtypes of WS have been described thus far. WS type I (WS1; OMIM 193500) includes dystopia canthorum (an outward displacement of the inner canthi), and this feature distinguishes WS1 from WS type II (WS2; OMIM numbers 193510, 600193, 606662, 608890 and 611584 for 2A to 2E) (Pardono et al., 2003). WS type III (WS3; OMIM 148880) is similar to WS1 but includes musculoskeletal anomalies of the upper limbs. WS type IV (WS4; OMIM 277580, 613265, and 613266 for 4A to 4C) is similar to type I but has features of Hirschsprung disease (Wildhardt et al., 2013). Despite many efforts to clinically differentiate between the subtypes of WS by diagnostic criteria (Farrer et al., 1992), the rarity and highly varied expression has limited the ability to make an accurate diagnosis in individual patients. In addition, hearing loss and early graying are relatively common in the general population and are not specific to WS (Ouyang et al., 2009).

### TABLE 2 Primer pairs of the novel mutations of MITF and SOX10

| Gene exon | Forward primer sequence (5′–3′) | Reverse primer sequence (5′–3′) | Product length |
|-----------|--------------------------------|-------------------------------|----------------|
| MITF-exon9 | GTGCTCTGCTATTTTCAGTTTTTA | AGGGAGATTGCGTAAACAGTG | 457 bp |
| SOX10-exon2 | GTGGGCCCTGAGCTTCTTGG | CTACCTGAATCCACCCGAA | 571 bp |
| SOX10-exon3 | CATCTCTCAGTCACAAATCTAGG | CCATCTCCTGTCTCCACTGACTG | 506 bp |
Thus, the accuracy of WS diagnosis needs to be improved by using additional diagnostic procedures. 

**MITF** is expressed in melanocytes and encodes a transcription factor containing the helix–loop–helix–leucine zipper structure. It is also a key factor in regulating the growth of melanocytes. Defects in melanocytes result in abnormal pigment distribution, whereas defects in melanocytes of the stria vascularis lead to WS2A (Curran, Raible, & Lister, 2009). **MITF** mutations are also observed in Tietz syndrome (albinism-deafness syndrome) (Smith, Kelley, Kenyon, & Hoover, 2000). Most WS-associated **MITF** mutations are located in exons 7–9 that correspond to the basic helix–loop–helix–Zip motifs (Read & Newton, 1997; Tassabehji, Newton, & Read, 1994). The mutants may impair transcriptional activities, phosphorylation, the capacity of DNA binding and nuclear localization (Smith et al., 2000; Takeda et al., 2000; Wilkie, 1994). It seems more likely to result in haploinsufficiency of **MITF** function, with consequent downregulation of tyrosinase expression (Morell et al., 1997). **SOX10**, the SRY-related transcription factor, binds to the **MITF** promoter and directly activates the expression of **MITF** (Verastegui, Bille, Ortonne, & Ballotti, 2000). Mutations in these two genes, therefore, are likely involved in the pathogenesis of WS2 through the same pathway and produce similar clinical phenotypes.

In this study, we identified two novel **MITF** heterozygous variations: c.859G>T (p.E287X) and c.859-1G>A. The c.859G>T (p.E287X) mutation is a nonsense mutation in which the glutamic acid is replaced with a stop codon substitution at codon 287. The c.859-1G>A is a splicing mutation. The two mutations are located in exon 9 of **MITF** at the intervening sequence of the leucine zipper and the third transactivation domain (AD3) of the protein. The two mutations were predicted to be disease-causing by in silico analysis using Mutation Taster, with a *p*-value of 1.0, suggesting a high possibility of protein functional alteration, which has not been previously reported. These variants co-segregated with all affected individuals (WS01-I:2, WS01-II:3, WS02-I:1, and WS02-II:1 and WS02-II:2) of their families and were not observed in unaffected members (WS01-II:1 and WS02-II:3). Meanwhile, we identified four novel **SOX10** heterozygous variations: c.355_356insTCAGGCAGCGC, c.1106_1107insTGGGCCCCCACACTA, c.511T>C (p.Y171H) and c.91_100del. Three were frameshift mutations and one was a missense mutation. These mutations were predicted to be disease causing by in silico analysis using Mutation Taster. The c.355_356insTCAGGCAGCGC mutation detected in WS03-I:2 co-segregated with all affected individuals (WS03-II:1 and WS03-II:2) of the family and was not observed in unaffected members (WS03-II:3). None of the proband’s parents (WS04-WS06) carried the corresponding mutations.

We subsequently verified that these six mutations did not exist in any of the widely used genomic databases (dbSNP, ...
the 1000 Genomes Project, ExAC, gnomAD) and 200 unrelated healthy control subjects. According to the American College of Medical Genetics and Genomics (ACMG) standard and guidelines 2015 (Richards et al., 2015), the five variants (except SOX10 c.511T>C) are pathogenic and their pathogenicity evidence grade PVS1 are high, and c.511T>C (p.Y171H) of SOX10 is likely pathogenic (PS2+PM2+PP3).

In our study, three of the four WS2 probands (WS04-06) with SOX10 mutations were not detected in either of the proband's parents, suggesting that the mutations occurred de novo. By parental genotyping, we revealed an interesting inheritance pattern, as de novo mutations were frequently found in probands with SOX10 mutations (3/4) but not in those with MITF mutations (0/2). The high de novo rates of
SOX10 mutations in WS2 may need special attention during the course of genetic diagnosis and counseling, as it can be initially mistaken as recessive inheritance prior to testing or be interpreted with over-estimated recurrent risk without further parental testing.

In conclusion, we investigated the clinical and genetic characteristics of six families of WS2 in China. We identified six pathogenic variants in the MITF and SOX10, which have not been previously reported in the Chinese population. This report will contribute to a better understanding of the WS mutation spectrum identified so far. We also demonstrated that NGS is a useful tool for the identification of pathogenic gene variants in WS patients and for differentiation between WS and similar disorders. In addition to family genotyping, further functional studies are required to explore the genetic mechanism of these novel mutations.

ACKNOWLEDGMENTS
We thank our patients for their participation in this study. This research was supported by the First Affiliated Hospital of Zhengzhou University (Grant number: KS-2018-KY-36). We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ORCID
Shumin Ren https://orcid.org/0000-0002-3347-7097
Xiangdong Kong https://orcid.org/0000-0003-0030-7638

REFERENCES
Curran, K., Raible, D. W., & Lister, J. A. (2009). Foxd3 controls melanophore specification in the zebrafish neural crest by regulation of Mitf. Developmental Biology, 332(2), 408–417. https://doi.org/10.1016/j.ydbio.2009.06.010
Farrer, L. A., Grundfast, K. M., Amos, J., Arnos, K. S., Asher, J. H., Beighton, P., … Read, A. P. (1992). Waardenburg syndrome (WS) type I is caused by defects at multiple loci, one of which is near ALPP on chromosome 2: First report of the WS consortium. American Journal of Human Genetics, 50(5), 902–913.
Ku, C. S., Cooper, D. N., Polychronakos, C., Naidoo, N., Wu, M., & Soong, R. (2012). Exome sequencing: Dual role as a discovery and diagnostic tool. Annals of Neurology, 71(1), 5–14. https://doi.org/10.1002/ana.22647
Lee, H., Deignan, J. L., Dorrani, N., Strom, S. P., Kantarci, S., Quintero-Rivera, F., … Nelson, S. F. (2014). Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA, 312(18), 1880–1887. https://doi.org/10.1001/jama.2014.14604
Lohmann K., & Klein C. (2014). Next generation sequencing and the future of genetic diagnosis. Neurotherapeutics: Rho Journal of the American Society for Experimental NeuroTherapeutics, 11(4), 699–707. https://doi.org/10.1007/s13311-014-0288-8
Morell, R., Spritz, R. A., Ho, L., Pierpoint, J., Guo, W., Friedman, T. B., & Asher, J. H. Jr. (1997). Apparent digenic inheritance of Waardenburg syndrome type 2 (WS2) and autosomal recessive ocular albinism (AROA). Human Molecular Genetics, 6, 659–664. https://doi.org/10.1093/hmg/6.5.659
Ng, S. B., Buckingham, K. J., Lee, C., Bigham, A. W., Tabor, H. K., Dent, K. M., … Bamshad, M. J. (2010). Exome sequencing identifies the cause of a mendelian disorder. Nature Genetics, 42(1), 30–35. https://doi.org/10.1038/ng.499
Ng, S. B., Turner, E. H., Robertson, P. D., Flygare, S. D., Bigham, A. W., Lee, C., … Shendure, J. (2009). Targeted capture and massively parallel sequencing of 12 human exomes. Nature, 461(7261), 272–276. https://doi.org/10.1038/nature08250
Ouyang, X. M., Yan, D., Yuan, H. J., Pu, D., Du, L. L., Han, D. Y., & Liu, X. Z. (2009). The genetic bases for non-syndromic hearing loss among Chinese. Journal of Human Genetics, 54, 131–140. https://doi.org/10.1038/jhgf.2009.4
Pardono, E., van Bever, Y., van den Ende, J., Havrenne, P. C., Iughetti, P., Maestrelli, S. R., … Otto, P. A. (2003). Waardenburg syndrome: Clinical differentiation between types I and II. American Journal of Medical Genetics. Part A, 117A(3), 223–235. https://doi.org/10.1002/ajmg.a.10193
Pingault, V., Ente, D., Dastot-Le Moal, F., Goossens, M., Marlin, S., & Bondurand, N. (2010). Review and update of mutations causing Waardenburg syndrome. Human Mutation, 31(4), 391–406. https://doi.org/10.1002/humu.21211
Read, A. P., & Newton, V. E. (1997). Waardenburg syndrome. Journal of Medical Genetics, 34, 656–665. https://doi.org/10.1136/jmg.34.8.656
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., … Rehm, H. L. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine., 17(5), 405–423.
Smith, S. D., Kelley, P. M., Kenyon, J. B., & Hoover, D. (2000). Tietz syndrome (hypopigmentation/deafness) caused by mutation of MITF. Journal of Medical Genetics, 37, 446–448. https://doi.org/10.1136/jmg.37.6.446
Takeda, K., Takemoto, C., Kobayashi, I., Watanabe, A., Nobukuni, Y., Fisher, D. E., & Tachibana, M. (2000). Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. Human Molecular Genetics, 9(1), 125–132. https://doi.org/10.1093/hmg/9.1.125
Tassabehji, M., Newton, V. E., & Read, A. P. (1994). Waardenburg syndrome type 2 caused by mutations in the microphthalmia associated transcription factor gene by the Waardenburg syndrome type 2 gene, SOX10. Nature, 373, 251–255. https://doi.org/10.1038/ng1194-251
Verastegui, C., Bille, K., Ortonne, J. P., & Ballotti, R. (2000). Regulation of the microphthalmia associated transcription factor gene by the Waardenburg syndrome type 4 gene, SOX10. Journal of Biological Chemistry, 275(40), 30757–30760. https://doi.org/10.1074/jbc.C000445200
Waardenburg, P. J. (1951). A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root with pigmen- tary defects of the iris and head hair and with congenital deafness. American Journal of Human Genetics, 3(3), 195–253.
Wildhardt, G., Zirn, B., Graul-Neumann, L. M., Wechtenbruch, J., Suckfüll, M., Buske, A., … Steinberger, D. (2013). Spectrum of novel mutations found in Waardenburg syndrome types 1 and 2: Implications for molecular genetic diagnostics. British Medical
How to cite this article: Ren S, Chen X, Kong X, et al. Identification of six novel variants in Waardenburg syndrome type II by next-generation sequencing. *Mol Genet Genomic Med*. 2020;8:e1128. [https://doi.org/10.1002/mgg3.1128](https://doi.org/10.1002/mgg3.1128)

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section.

Wilkie, A. O. (1994). The molecular basis of genetic dominance. *Journal of Medical Genetics*, 31, 89–98. [https://doi.org/10.1136/jmg.31.2.89](https://doi.org/10.1136/jmg.31.2.89)